Skip to main content

Advertisement

SpringerLink
Log in

Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Systemic sclerosis (SSc) is a chronic inflammatory disease with complex pathogenesis, based on the sophisticated interplay of injury to the vascular endothelium, exaggerated tissue regeneration and fibrosis, and extensive immune abnormalities. The role of regulatory T cells (Tregs) in the development of SSc has started being studied during the last decade with new aspects being disclosed continuously, in parallel with the better understanding of Tregs physiology. There is a general agreement in the medical literature regarding the decreased functional capacity of circulating Tregs in SSc. Some patients, particularly those with active disease, may have increased numbers of circulating Tregs, representing the inhibitory response of the immune system to its inappropriate activation or occurring as a compensatory move for Tregs’ decreased suppressive ability. Decreased pool of circulating Tregs can be seen in other SSc patients, with even lower Treg percentages seen in patients with long-standing disease. Skin-resident Tregs are depleted in advanced SSc but can be active and have a role in earlier disease stages. In addition to diminished suppressive ability, Tregs can contribute to SSc evolution by their microenvironment-dependent transformation to pathogenic effector T cells of Th17 or Th2 lineages with respective pro-inflammatory or pro-fibrotic activity. The current data on the effects of existing treatment modalities, including autologous stem cell transplantation, on Tregs function in SSc, is controversial, not being sufficiently elaborated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165–170

    Article  PubMed  Google Scholar 

  2. Elhai M, Avouac J, Walker UA et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75(1):163–169

    Article  PubMed  Google Scholar 

  3. Denton CP (2015) Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 33(4 Suppl 92):S3–S7

    PubMed  Google Scholar 

  4. Krieg T, Takehara K (2009) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii14–iii18

    Google Scholar 

  5. Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815

    Article  PubMed  Google Scholar 

  6. Desbois AC, Cacoub P (2016) Systemic sclerosis: an update in 2016. Autoimmun Rev 15:417–426

    Article  PubMed  Google Scholar 

  7. Meier FM, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360

    Article  PubMed  Google Scholar 

  8. Coghlan JG, Denton CP, Grunig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340–1349

    Article  PubMed  Google Scholar 

  9. Amaral TN, Peres FA, Lapa AT et al (2013) Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 43:335–347

    Article  PubMed  Google Scholar 

  10. Maurer B, Distler A, Suliman YA et al (2014) Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 73:1880–1887

    Article  PubMed  Google Scholar 

  11. Kawaguchi Y, Suzuki K, Hara M et al (1994) Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 53(8):506–510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lee R, Reese C, Perry B et al (2015) Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1. Fibrogenesis Tissue Repair 8:11. doi:10.1186/s13069-015-0028-7

    Article  PubMed  PubMed Central  Google Scholar 

  13. Van Bon L, Affandi AJ, Broen J et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433–443

    Article  PubMed  Google Scholar 

  14. Pisitkun P, Deane JA, Difilippantonio MJ et al (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312(5780):1669–1672

    Article  CAS  PubMed  Google Scholar 

  15. Eloranta ML, Franck-Larsson K, Lövgren T et al (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69(7):1396–1402

    Article  CAS  PubMed  Google Scholar 

  16. Dimitroulas T, Daoussis D, Garyfallos A, Sfikakis PP, Kitas GD (2015) Molecular and cellular pathways as treatment targets for biologic therpaies in systemic sclerosis. Curr Med Chem 22(16):1943–1955

    Article  CAS  PubMed  Google Scholar 

  17. Gottenberg JE, Chiocchia G (2007) Dendritic cells and interferon-mediated autoimmunity. Biochimie 89(6-7):856–871

    Article  CAS  PubMed  Google Scholar 

  18. Huang XL, Wang YJ, Yan JW et al (2015) Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res 64(3-4):151–159

    Article  CAS  PubMed  Google Scholar 

  19. Liu M, Yang J, Xing X et al (2014) Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther 16(6):4223

    Article  PubMed  PubMed Central  Google Scholar 

  20. Stummvoll GH, Aringer M, Smolen JS et al (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39(12):1341–1350

    Article  CAS  Google Scholar 

  21. Nie J, Li YY, Zheng SG et al (2015) FOXP3(+) Treg Cells and Gender Bias in Autoimmune Diseases. Front Immunol 6:493. doi:10.3389/fimmu.2015.00493

    Article  PubMed  PubMed Central  Google Scholar 

  22. Liston A, Gray DH (2014) Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 14(3):154–165

    Article  CAS  PubMed  Google Scholar 

  23. Chizzolini C, Boin F (2015) The role of the acquired immune response in systemic sclerosis. Semin Immunopathol 37(5):519–528

    Article  CAS  PubMed  Google Scholar 

  24. Ohkura N, Hamaguchi M, Morikawa H et al (2012) T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37(5):785–799

    Article  CAS  PubMed  Google Scholar 

  25. Amado IF, Berges J, Luther RJ et al (2013) IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 210(12):2707–2720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911

    Article  CAS  PubMed  Google Scholar 

  27. Pesenacker AM, Broady R, Levings MK (2014) Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 45(2):333–343

    Article  PubMed  Google Scholar 

  28. Sanchez Rodriguez R, Pauli ML, Neuhaus IM et al (2014) Memory regulatory T cells reside in human skin. J Clin Invest 124(3):1027–1036

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nomura T, Kabashima K, Miyachi Y (2014) The panoply of αβT cells in the skin. J Dermatol Sci 76(1):3–9

    Article  CAS  PubMed  Google Scholar 

  30. Seneschal J, Clark RA, Gehad A et al (2012) Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36(5):873–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dudda JC, Perdue N, Bachtanian E et al (2008) Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J Exp Med 205(7):1559–1565

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Stary G, Klein I, Bauer W et al (2011) Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. J Immunol 186(1):103–112

    Article  CAS  PubMed  Google Scholar 

  33. Chu CC, Ali N, Karagiannis P et al (2012) Resident CD141 (BDCA3) + dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 209(5):935–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Tomura M, Honda T, Tanizaki H et al (2010) Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 120(3):883–893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sawant DV, Vignali DA (2014) Once a Treg, always a Treg? Immunol Rev 259(1):173–191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pesenacker AM, Bending D, Ursu S et al (2013) CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood 121(14):2647–2658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Duhen T, Duhen R, Lanzavecchia A et al (2012) Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119(19):4430–4440

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186(7):3918–3926

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Radstake TR, van Bon L, Broen J et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 4(6):e5981

    Article  PubMed  PubMed Central  Google Scholar 

  40. Simonetta F, Chiali A, Cordier C et al (2010) Increased CD127 expression on activated FOXP3 + CD4+ regulatory T cells. Eur J Immunol 40(9):2528–2538

    Article  CAS  PubMed  Google Scholar 

  41. Giovannetti A, Rosato E, Renzi C et al (2010) Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 137(1):122–133

    Article  CAS  PubMed  Google Scholar 

  42. Slobodin G, Ahmad MS, Rosner I et al (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261(2):77–80

    Article  CAS  PubMed  Google Scholar 

  43. Liu X, Gao N, Li M et al (2013) Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One 8(6):e64531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Jiang N, Li M, Zeng X (2014) Correlation of Th17 cells and CD4+CD25+ regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J (Engl) 127(20):3557–3561

    Google Scholar 

  45. Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J et al (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32(9):2653–2660

    Article  PubMed  Google Scholar 

  46. Klein S, Kretz CC, Krammer PH et al (2010) CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 130(2):492–499

    Article  CAS  PubMed  Google Scholar 

  47. Klein S, Kretz CC, Ruland V et al (2011) Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 70(8):1475–1481

    Article  CAS  PubMed  Google Scholar 

  48. Banica L, Besliu A, Pistol G et al (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42(1):41–49

    Article  CAS  PubMed  Google Scholar 

  49. Antiga E, Quaglino P, Bellandi S et al (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 162(5):1056–1063

    Article  CAS  PubMed  Google Scholar 

  50. Papp G, Horvath IF, Barath S et al (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40(3):205–210

    Article  CAS  PubMed  Google Scholar 

  51. Fenoglio D, Battaglia F, Parodi A et al (2011) Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 139(3):249–257

    Article  CAS  PubMed  Google Scholar 

  52. Cordiali-Fei P, Mussi A, D’Agosto G et al (2013) Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol 2013:390563

    Article  PubMed  PubMed Central  Google Scholar 

  53. Reiff A, Weinberg KI, Triche T et al (2013) T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol 149(1):146–155

    Article  CAS  PubMed  Google Scholar 

  54. Mathian A, Parizot C, Dorgham K et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71(7):1227–1234

    Article  CAS  PubMed  Google Scholar 

  55. Kataoka H, Yasuda S, Fukaya S et al (2015) Decreased expression of Runx1 and lowered proportion of Foxp3+ CD25+ CD4+ regulatory T cells in systemic sclerosis. Mod Rheumatol 25(1):90–95

    Article  CAS  PubMed  Google Scholar 

  56. Michels-van Amelsfort JM, Walter GJ, Taams LS (2011) CD4 + CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases. Expert Rev Clin Immunol 7(4):499–514

    Article  CAS  PubMed  Google Scholar 

  57. Antiga E, Fabbri P, Caproni M (2010) Immunosuppressive therapy may affect the number of circulating regulatory cells in systemic sclerosis: pay attention to the patient selection criteria. Cell Immunol 264(2):186

    Article  CAS  PubMed  Google Scholar 

  58. D’Amelio P, Cristofaro MA, D’Amico L et al (2010) Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 11:62

    Article  PubMed  PubMed Central  Google Scholar 

  59. Papp G, Horvath IF, Barath S et al (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142(2):150–159

    Article  CAS  PubMed  Google Scholar 

  60. Papp G, Barath S, Szegedi A et al (2012) The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 31(9):1293–1299

    Article  PubMed  Google Scholar 

  61. Tsukamoto H, Nagafuji K, Horiuchi T et al (2011) Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Rheumatology (Oxford) 50(5):944–952

    Article  CAS  Google Scholar 

  62. Baraut J, Grigore EI, Jean-Louis F et al (2014) Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 49(3):349–354

    Article  CAS  PubMed  Google Scholar 

  63. Szodoray P, Varoczy L, Papp G et al (2012) Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol 41(2):110–115

    Article  CAS  PubMed  Google Scholar 

  64. Delemarre EM, van den Broek T, Mijnheer G et al (2016) Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood 127(1):91–101

    Article  CAS  PubMed  Google Scholar 

  65. Broen JC, Wolvers-Tettero IL, Geurts-van Bon L et al (2010) Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis 69(12):2213–2216

    Article  CAS  PubMed  Google Scholar 

  66. Wang YY, Wang Q, Sun XH et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171(1):39–47

    Article  CAS  PubMed  Google Scholar 

  67. Giovannetti A, Maselli A, Colasanti T et al (2013) Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One 8(9):e74332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Rimar D, Nov Y, Rosner I et al (2015) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35(10):1625–1630

    Article  CAS  PubMed  Google Scholar 

  69. Khoury SJ (2011) Th17 and Treg balance in systemic sclerosis. Clin Immunol 139(3):231–232

    Article  CAS  PubMed  Google Scholar 

  70. Liu M, Wu W, Sun X, et al. (2016) New insights into CD4(+) T cell abnormalities in systemic sclerosis. Cytokine Growth Factor Rev 28:31–36

  71. Yang X, Yang J, Xing X et al (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16(1):R4

    Article  PubMed  PubMed Central  Google Scholar 

  72. MacDonald KG, Dawson NA, Huang Q et al (2015) Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 135(4):946, e9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology, Bnai Zion Medical Center, Haifa, Israel

    Gleb Slobodin & Doron Rimar

  2. Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    Gleb Slobodin & Doron Rimar

Authors
  1. Gleb Slobodin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doron Rimar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gleb Slobodin.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Slobodin, G., Rimar, D. Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review. Clinic Rev Allerg Immunol 52, 194–201 (2017). https://doi.org/10.1007/s12016-016-8563-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8563-6

Keywords

Search

Navigation